PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15329635

A nurse-managed universal newborn hearing screen program.

Rita Allen Brennan
View original source ↗Export metadata ↓

Abstract

Hearing loss is one of the most common major birth defects, yet the average age for identifying significant hearing loss in children in the United States is 30 months. Hearing loss directly affects a child's ability to develop normal language skills, impairs his or her ability to communicate with others in the environment, and has been shown to correlate with poor academic performance. However, if hearing loss is detected early and interventions are begun before 6 months of age, children with hearing loss develop language, cognitive, and speech skills comparable to their non-hearing-impaired peers. Only 38 states mandate universal newborn hearing screening before discharge from the hospital. This article describes an institutional universal hearing screening program developed by nursing, which collaborated with physicians, audiologists, and otolaryngologists. Careful planning, including a thorough literature review, networking with area hospitals, and dialoging with experts in the field led to a successful program.The outcomes from this program compare favorably to nationally published data.

Explore related subjects

Developmental DisabilitiesHearing DisordersHearing TestsHumansInfantInfant, NewbornMaternal-Child NursingNeonatal ScreeningNurse's RoleNursing AssessmentNursing Methodology ResearchUnited StatesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rita Allen Brennan. A nurse-managed universal newborn hearing screen program.. https://doi.org/10.1097/00005721-200409000-00011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Replacement of estrogens and progestins to prevent morbidity and mortality in preterm infants.

BACKGROUND: A potential therapeutic effect of sex steroids on premature infants has been proposed from animal data and observational studies in humans. Purported benefits include reduction in chronic lung disease, improved bone density and improved neurodevelopmental outcome. OBJECTIVES: To determine if estrogens or progestins, either alone or in combination, when compared to placebo or no treatment, reduce morbidity and/or mortality in preterm infants. SEARCH STRATEGY: The standard search strategy of the Cochrane Neonatal Review Group as outlined in the Cochrane Library (Issue 2, 2004) was used. This included searches of the Oxford Database of Perinatal Trials, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2004), MEDLINE 1966 to July 2004 inclusive, previous reviews including cross references, abstracts, conferences and symposia proceedings (Perinatal Society of Australia and New Zealand 1998-2004 and Pediatric Academic Societies meetings 1998-2004). SELECTION CRITERIA: Randomised controlled trials comparing the use of estrogens and/or progestins with placebo or no treatment in preterm infants born less than 30 weeks gestation were included in this review. The primary outcome measures were neonatal mortality and medium-term neurodevelopmental outcome. Other outcomes included length of hospital stay, incidence of chronic lung disease, osteopaenia causing fractures and adverse effects of sex steroid administration. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected, assessed the quality of and extracted data from the included studies. Meta-analyses were performed using relative risk and risk difference for dichotomous data, and weighted mean difference for continuous data with 95% confidence intervals. MAIN RESULTS: Two randomised controlled trials were identified by the search strategy and one was included in this review, comprising 30 preterm infants. There was no significant effect of replacement of estradiol and progesterone on the outcomes of mortality or neurodevelopmental disability in survivors followed. No adverse effects of sex steroid replacement on short or longer term outcomes were detected. REVIEWERS' CONCLUSIONS: The one small randomised controlled trial demonstrated neither evidence of benefit or harm related to the replacement of estradiol and progesterone in preterm infants less than 30 weeks gestation. A properly powered randomised controlled trial is required to determine whether or not administration of estradiol or progesterone, either alone or in combination, and at varying doses, confers any clinically significant benefits, or poses any risk, to the preterm infant.

Developmental Disabilities↗
PubMed2004

Choroid plexus papilloma associated with developmental delay.

Choroid plexus papillomas are rare, benign tumors of neuroectodermal origin usually observed in the lateral ventricles of children. The usual presenting signs of choroid plexus papillomas are related to hydrocephalus and increased intracranial pressure. A child presented to us with clinical features of delayed milestones, which was later diagnosed as a case of choroid plexus papilloma with hydrocephalus. He underwent complete excision of the tumour with gradual recovery of milestones.

Developmental Disabilities↗
PubMed2004

Normal vernier acuity in infants with delayed visual maturation.

PURPOSE: Measures of vernier acuity may correlate accurately with measures of Snellen acuity. We used the sweep visual evoked potential to determine whether vernier acuity is normal in children with delayed visual maturation (DVM). DESIGN: Case series of two infants. METHODS: Thresholds for grating and vernier acuity were measured electrophysiologically in two infants with DVM using the sweep visual evoked potential. Acuity thresholds were calculated for each of these visual functions. RESULTS: Two infants with DVM had normal thresholds for grating and vernier acuity, even though their visual behavior as determined clinically was abnormal. CONCLUSIONS: Some children with DVM have normal acuity thresholds, even though the behaviors associated with vision are delayed or absent.

Developmental Disabilities↗